The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.

This study is a randomized, double-blind, placebo-controlled, parallel-dose clinical trial. Participants will be randomly assigned to one of three groups. Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.

Inclusion Criteria:

• >= 35 and <=70
• Provides consent to participate in the study
• Not pregnant at time of consent
• Understands and agrees to follow all study procedures and limitations
• Have no contraindicating comorbid health condition as determined by the clinical investigators

Exclusion Criteria:

• Pregnant, nursing, or trying to conceive
• BMI Restrictions: <35
• Allergy or sensitivity to study agent ingredients
• Hypertension treated with medication
• Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
• Surgery planned during the course of the trial
• History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke
• History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
• Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index >40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as >2 kg change in body mass).
• An unstable medical or mental health condition as determined by the physician investigator.

The pharmacy will be responsible for randomization and dispensing appropriate randomized intervention.